Cirrhosis Diagnosis and Liver Fibrosis Staging: Transient Elastometry Versus Cirrhosis Blood Test
- PMID: 24828359
- DOI: 10.1097/MCG.0000000000000138
Cirrhosis Diagnosis and Liver Fibrosis Staging: Transient Elastometry Versus Cirrhosis Blood Test
Abstract
Introduction: Elastometry is more accurate than blood tests for cirrhosis diagnosis. However, blood tests were developed for significant fibrosis, with the exception of CirrhoMeter developed for cirrhosis. We compared the performance of Fibroscan and CirrhoMeter, and classic binary cirrhosis diagnosis versus new fibrosis staging for cirrhosis diagnosis.
Methods: The diagnostic population included 679 patients with hepatitis C and liver biopsy (Metavir staging and morphometry), Fibroscan, and CirrhoMeter. The prognostic population included 1110 patients with chronic liver disease and both tests.
Results: Binary diagnosis: AUROCs for cirrhosis were: Fibroscan: 0.905; CirrhoMeter: 0.857; and P=0.041. Accuracy (Youden cutoff) was: Fibroscan: 85.4%; CirrhoMeter: 79.2%; and P<0.001. Fibrosis classification provided 6 classes (F0/1, F1/2, F2±1, F3±1, F3/4, and F4). Accuracy was: Fibroscan: 88.2%; CirrhoMeter: 88.8%; and P=0.77. A simplified fibrosis classification comprised 3 categories: discrete (F1±1), moderate (F2±1), and severe (F3/4) fibrosis. Using this simplified classification, CirrhoMeter predicted survival better than Fibroscan (respectively, χ=37.9 and 19.7 by log-rank test), but both predicted it well (P<0.001 by log-rank test). Comparison: binary diagnosis versus fibrosis classification, respectively, overall accuracy: CirrhoMeter: 79.2% versus 88.8% (P<0.001); Fibroscan: 85.4% versus 88.2% (P=0.127); positive predictive value for cirrhosis by Fibroscan: Youden cutoff (11.1 kPa): 49.1% versus cutoffs of F3/4 (17.6 kPa): 67.6% and F4 classes (25.7 kPa): 82.4%.
Conclusions: Fibroscan's usual binary cutoffs for cirrhosis diagnosis are not sufficiently accurate. Fibrosis classification should be preferred over binary diagnosis. A cirrhosis-specific blood test markedly attenuates the accuracy deficit for cirrhosis diagnosis of usual blood tests versus transient elastometry, and may offer better prognostication.
Similar articles
-
Improved fibrosis staging by elastometry and blood test in chronic hepatitis C.Liver Int. 2014 Jul;34(6):907-17. doi: 10.1111/liv.12327. Epub 2013 Oct 16. Liver Int. 2014. PMID: 24102852
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.Am J Gastroenterol. 2011 Jul;106(7):1255-63. doi: 10.1038/ajg.2011.100. Epub 2011 Apr 5. Am J Gastroenterol. 2011. PMID: 21468012 Clinical Trial.
-
Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2025 Apr;10(4):332-349. doi: 10.1016/S2468-1253(24)00437-0. Epub 2025 Feb 18. Lancet Gastroenterol Hepatol. 2025. PMID: 39983746
-
Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):443-50. doi: 10.1097/MPG.0b013e31812e56ff. J Pediatr Gastroenterol Nutr. 2007. PMID: 18030211 Clinical Trial.
-
[Results and place of Fibroscan in the non-invasive diagnosis of hepatic fibrosis].Rev Med Interne. 2007 Feb;28(2):94-102. doi: 10.1016/j.revmed.2006.10.329. Epub 2006 Nov 3. Rev Med Interne. 2007. PMID: 17137680 Review. French.
Cited by
-
A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis.Hepatol Commun. 2018 Mar 5;2(4):455-466. doi: 10.1002/hep4.1161. eCollection 2018 Apr. Hepatol Commun. 2018. PMID: 29619423 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous